3D absorbed dose calculations based on SPECT: Evaluation for 111-In/90-Y therapy using Monte Carlo simulations

Michael Ljungberg, Eric Frey, Katarina Sjögreen, Xiaowei Liu, Yuni Dewaraja, Sven Erik Strand

Research output: Contribution to journalArticle

Abstract

A general method is presented for patient-specific three-dimensional (3D) absorbed dose calculations based on quantitative SPECT activity measurements. The computational scheme includes a method for registration of the CT study to the SPECT image, and compensation for attenuation, scatter, and collimator-detector response including septal penetration, performed as part of an iterative reconstruction method. From SPECT images, the absorbed dose rate is calculated using an EGS4 Monte Carlo code, which converts the activity distribution to an absorbed dose rate distribution. Evaluation of the accuracy in the activity quantification and the absorbed dose calculation is based on realistic Monte Carlo simulated SPECT data of a voxel-computer phantom and 111In and 90Y. Septal penetration was not included in this study. The SPECT-based activity concentrations and absorbed dose distributions are compared to the actual values; the results imply that the corrections for attenuation and scatter yield results of high accuracy. The presented method includes compensation for most parameters deteriorating the quantitative image information. Inaccuracies are, however, introduced by the limited spatial resolution of the SPECT system, which are not fully compensated by the collimator-response correction. The proposed evaluation methodology may be used as a basis for future inter-comparison of different dosimetry calculation schemes.

Original languageEnglish (US)
Pages (from-to)99-107
Number of pages9
JournalCancer Biotherapy and Radiopharmaceuticals
Volume18
Issue number1
StatePublished - 2003
Externally publishedYes

Fingerprint

Single-Photon Emission-Computed Tomography
Therapeutics

Keywords

  • Attenuation
  • Dosimetry
  • Monte Carlo
  • Quantification
  • Scatter
  • Simulation
  • SPECT

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

3D absorbed dose calculations based on SPECT : Evaluation for 111-In/90-Y therapy using Monte Carlo simulations. / Ljungberg, Michael; Frey, Eric; Sjögreen, Katarina; Liu, Xiaowei; Dewaraja, Yuni; Strand, Sven Erik.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 18, No. 1, 2003, p. 99-107.

Research output: Contribution to journalArticle

Ljungberg, Michael ; Frey, Eric ; Sjögreen, Katarina ; Liu, Xiaowei ; Dewaraja, Yuni ; Strand, Sven Erik. / 3D absorbed dose calculations based on SPECT : Evaluation for 111-In/90-Y therapy using Monte Carlo simulations. In: Cancer Biotherapy and Radiopharmaceuticals. 2003 ; Vol. 18, No. 1. pp. 99-107.
@article{403467bdbf124ff6aa86631095a90e3f,
title = "3D absorbed dose calculations based on SPECT: Evaluation for 111-In/90-Y therapy using Monte Carlo simulations",
abstract = "A general method is presented for patient-specific three-dimensional (3D) absorbed dose calculations based on quantitative SPECT activity measurements. The computational scheme includes a method for registration of the CT study to the SPECT image, and compensation for attenuation, scatter, and collimator-detector response including septal penetration, performed as part of an iterative reconstruction method. From SPECT images, the absorbed dose rate is calculated using an EGS4 Monte Carlo code, which converts the activity distribution to an absorbed dose rate distribution. Evaluation of the accuracy in the activity quantification and the absorbed dose calculation is based on realistic Monte Carlo simulated SPECT data of a voxel-computer phantom and 111In and 90Y. Septal penetration was not included in this study. The SPECT-based activity concentrations and absorbed dose distributions are compared to the actual values; the results imply that the corrections for attenuation and scatter yield results of high accuracy. The presented method includes compensation for most parameters deteriorating the quantitative image information. Inaccuracies are, however, introduced by the limited spatial resolution of the SPECT system, which are not fully compensated by the collimator-response correction. The proposed evaluation methodology may be used as a basis for future inter-comparison of different dosimetry calculation schemes.",
keywords = "Attenuation, Dosimetry, Monte Carlo, Quantification, Scatter, Simulation, SPECT",
author = "Michael Ljungberg and Eric Frey and Katarina Sj{\"o}green and Xiaowei Liu and Yuni Dewaraja and Strand, {Sven Erik}",
year = "2003",
language = "English (US)",
volume = "18",
pages = "99--107",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - 3D absorbed dose calculations based on SPECT

T2 - Evaluation for 111-In/90-Y therapy using Monte Carlo simulations

AU - Ljungberg, Michael

AU - Frey, Eric

AU - Sjögreen, Katarina

AU - Liu, Xiaowei

AU - Dewaraja, Yuni

AU - Strand, Sven Erik

PY - 2003

Y1 - 2003

N2 - A general method is presented for patient-specific three-dimensional (3D) absorbed dose calculations based on quantitative SPECT activity measurements. The computational scheme includes a method for registration of the CT study to the SPECT image, and compensation for attenuation, scatter, and collimator-detector response including septal penetration, performed as part of an iterative reconstruction method. From SPECT images, the absorbed dose rate is calculated using an EGS4 Monte Carlo code, which converts the activity distribution to an absorbed dose rate distribution. Evaluation of the accuracy in the activity quantification and the absorbed dose calculation is based on realistic Monte Carlo simulated SPECT data of a voxel-computer phantom and 111In and 90Y. Septal penetration was not included in this study. The SPECT-based activity concentrations and absorbed dose distributions are compared to the actual values; the results imply that the corrections for attenuation and scatter yield results of high accuracy. The presented method includes compensation for most parameters deteriorating the quantitative image information. Inaccuracies are, however, introduced by the limited spatial resolution of the SPECT system, which are not fully compensated by the collimator-response correction. The proposed evaluation methodology may be used as a basis for future inter-comparison of different dosimetry calculation schemes.

AB - A general method is presented for patient-specific three-dimensional (3D) absorbed dose calculations based on quantitative SPECT activity measurements. The computational scheme includes a method for registration of the CT study to the SPECT image, and compensation for attenuation, scatter, and collimator-detector response including septal penetration, performed as part of an iterative reconstruction method. From SPECT images, the absorbed dose rate is calculated using an EGS4 Monte Carlo code, which converts the activity distribution to an absorbed dose rate distribution. Evaluation of the accuracy in the activity quantification and the absorbed dose calculation is based on realistic Monte Carlo simulated SPECT data of a voxel-computer phantom and 111In and 90Y. Septal penetration was not included in this study. The SPECT-based activity concentrations and absorbed dose distributions are compared to the actual values; the results imply that the corrections for attenuation and scatter yield results of high accuracy. The presented method includes compensation for most parameters deteriorating the quantitative image information. Inaccuracies are, however, introduced by the limited spatial resolution of the SPECT system, which are not fully compensated by the collimator-response correction. The proposed evaluation methodology may be used as a basis for future inter-comparison of different dosimetry calculation schemes.

KW - Attenuation

KW - Dosimetry

KW - Monte Carlo

KW - Quantification

KW - Scatter

KW - Simulation

KW - SPECT

UR - http://www.scopus.com/inward/record.url?scp=0037222431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037222431&partnerID=8YFLogxK

M3 - Article

C2 - 12667313

AN - SCOPUS:0037222431

VL - 18

SP - 99

EP - 107

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 1

ER -